Skip to main content
Premium Trial:

Request an Annual Quote

German Firms Evotec, Definiens to Co-develop Cellular Assay-analysis Platform

NEW YORK, July 31 - German text-mining software provider Definiens and genomics-tool maker Evotec Technologies will co-develop an informatics-based platform for cellular-assay analysis and drug discovery.


To facilitate the collaboration, designed to enable researchers to perform high throughput screening of assays in cell biology, Evotec will ensure that its Libretto software will be compatible with Definiens Cellenger platform. According to Definiens, the Challenger software enables researchers to perform automated tissue and cellular-assay analysis.


Evotec's confocal  microplate analyzer for image detection, called Opera, will also be folded into the development project. "Cellenger further extends Opera's capabilities as an open platform for cell biology experimentation, and with our  open software architecture we could implement this extension quickly" said Evotec CSO Rolf G nther.


Added Uli Berresheim, CEO of  Definiens: "We are going to create a system that will automatically provide the user with valuable information about cells, cell components, and their mutual relations."


The companies expect to launch the platform by the end of September. Financial details of the deal were not disclosed.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.